OverviewSuggest Edit

Amgen (formerly known as Applied Molecular Genetics) is a biotech company discovering, developing, manufacturing, and delivering human therapeutics products. It focuses on oncology and hematology, cardiovascular, inflammation, bone health, and neuroscience diseases. Its major brands include:

TypePublic
Founded1980
HQThousand Oaks, CA, US
Websiteamgen.com
Employee Ratings4
Overall CultureF

Latest Updates

Employees (est.) (Dec 2019)23,400(+9%)
Job Openings886
Revenue (FY, 2020)$25.4 B(+9%)
Share Price (May 2021)$254.2(+4%)

Key People/Management at Amgen

Robert A. Bradway

Robert A. Bradway

Chairman and Chief Executive Officer
Victoria H. Blatter

Victoria H. Blatter

Senior Vice President, U.S. Government Affairs
Judy Gawlik Brown

Judy Gawlik Brown

Senior Vice President, Corporate Affairs
Tia Bush

Tia Bush

Senior Vice President, Quality
Raymond Deshaies

Raymond Deshaies

Senior Vice President, Global Research
Steven K. Galson

Steven K. Galson

Senior Vice President, Research and Development
Show more

Amgen Office Locations

Amgen has offices in Thousand Oaks, Cambridge, Louisville, South San Francisco and in 54 other locations
Thousand Oaks, CA, US (HQ)
1 Amgen Center Dr
Cambridge, MA, US
360 Binney St
Louisville, KY, US
12000 Plantside Dr
South San Francisco, CA, US
1120 Veterans Blvd
Tampa, FL, US
2202 N Westshore Blvd
Washington, DC, US
601 13th St NW 12th Floor
Show all (63)

Amgen Financials and Metrics

Amgen Revenue

Embed Graph
View revenue for all periods
Amgen's revenue was reported to be $25.42 b in FY, 2020
USD

Revenue (FY, 2020)

25.4b

Gross profit (FY, 2020)

19.3b

Gross profit margin (FY, 2020), %

75.8%

Net income (FY, 2020)

7.3b

EBIT (FY, 2020)

9.1b

Market capitalization (7-May-2021)

146.1b

Closing stock price (7-May-2021)

254.2

Cash (31-Dec-2020)

6.3b

EV

172.8b
Amgen's current market capitalization is $146.1 b.
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

23.0b22.8b23.7b23.4b25.4b

Revenue growth, %

6%(1%)4%(2%)

Cost of goods sold

4.2b4.1b4.1b4.4b6.2b

Gross profit

18.8b18.8b19.6b19.0b19.3b
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

5.5b5.8b5.8b5.6b6.1b5.9b5.6b5.9b5.7b6.2b6.2b6.4b

Cost of goods sold

996.0m1.0b990.0m944.0m1.0b1.0b1.1b1.0b1.0b1.5b1.5b1.6b

Gross profit

4.5b4.8b4.8b4.6b5.0b4.9b4.5b4.9b4.7b4.6b4.7b4.9b

Gross profit Margin, %

82%82%83%83%83%82%81%83%82%75%76%76%
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

3.2b3.8b6.9b6.0b6.3b

Accounts Receivable

3.2b3.2b3.6b4.1b4.5b

Inventories

2.7b2.8b2.9b3.6b3.9b

Current Assets

46.0b49.5b37.6b18.4b21.1b
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

3.4b2.6b3.0b9.7b10.1b12.0b7.4b5.5b11.4b7.7b9.1b9.1b

Accounts Receivable

3.2b3.6b3.4b3.6b3.5b3.4b3.8b3.8b3.6b5.0b5.4b4.1b

Inventories

2.9b3.0b2.9b3.0b3.1b3.0b3.0b3.2b3.2b3.7b3.8b3.9b

Current Assets

46.5b48.4b49.8b40.7b38.0b38.3b35.2b30.7b31.1b18.8b22.9b22.7b
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

7.7b2.0b8.4b7.8b7.3b

Depreciation and Amortization

2.1b2.0b1.9b2.2b3.6b

Inventories

(80.0m)133.0m(3.0m)(66.0m)(215.0m)

Accounts Payable

(44.0m)424.0m(143.0m)164.0m45.0m
USDFY, 2016

Revenue/Employee

1.2m

Debt/Equity

1.2 x

Debt/Assets

0.4 x

Financial Leverage

2.6 x
Show all financial metrics

Amgen Operating Metrics

Feb, 2016FY, 2016Feb, 2017FY, 2017Feb, 2018FY, 2018Feb, 2019FY, 2019Feb, 2020

Countries

100100100100

Facilities

190180190190

Patents (US)

22222734

Phase III Trials Products

1512151113781014
Show all operating metrics

Amgen Acquisitions / Subsidiaries

Company NameDateDeal Size
OtezlaNovember 19, 2019$13.4 b
NuevolutionMay 22, 2019
CatherexDecember 21, 2015
Dezima PharmaSeptember 16, 2015$300 m
Onyx PharmaceuticalsAugust 24, 2013$10.5 b
DeCODE GeneticsDecember 10, 2012$415 m
MN PharmaceuticalsApril 26, 2012$700 m
KAI PharmaceuticalsApril 10, 2012$315 m
MicrometJanuary 26, 2012
BergamoApril 08, 2011
Show more

Amgen Revenue Breakdown

Embed Graph

Amgen revenue breakdown by business segment: 22.4% from Enbrel, 13.8% from Neulasta, 11.4% from Prolia, 8.3% from XGEVA, 7.4% from Aranesp, 21.2% from Other products and 15.5% from Other

Amgen revenue breakdown by geographic segment: 25.5% from Rest of World and 74.5% from United States

Human Capital Metrics

Embed Graph
Show all human capital metrics

Amgen Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

60-79

out of 100

CSRHub logo

Amgen Online and Social Media Presence

Embed Graph

Amgen Company Culture

  • Overall Culture

    F

    43/100

  • CEO Rating

    F

    55/100

  • Compensation

    F

    10/100

Learn more on Comparably

Amgen News and Updates

Can Amgen Stock Rebound After The Recent 9% Fall?

Amgen's Q1 results didn’t bode well with the investors and the stock plunged over 7% in Wednesday’s trading session (April 28). But now that the stock has fallen 9% in just five days, will AMGN stock resume its downward trajectory over the coming weeks, or is a rise in the stock imminent?

Outlook on the C5 Complement Inhibitors Drug Global Market to 2026 - Featuring Amgen, Akari Therapeutics and Novartis Among Others

Dublin, April 30, 2021 (GLOBE NEWSWIRE) -- The "Global C5 Complement Inhibitors Drug Market Opportunity, Drug Price, Sales & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering.

Amgen Provides Updated Information On LUMAKRAS™ (Sotorasib)¹ Dose Comparison Study

THOUSAND OAKS, Calif., April 28, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it agreed last night with the FDA's proposed post-marketing requirement to conduct, as part of the ongoing development program, a multi-center randomized clinical trial to compare the safety and...

Global Pharmaceutical Manufacturing Industry (2020 to 2027) - Featuring Aenova Group, Amgen and AstraZeneca Among Others

Dublin, April 07, 2021 (GLOBE NEWSWIRE) -- The "Global Pharmaceutical Manufacturing Industry 2020-2027 by Formulation, Route of Administration, Age Group, Therapeutic Application, Drug Type, Distribution Channel, Manufacturing Facility, and Region: Trend Forecast and Growth Opportunity" report has…

Global Biologic Therapeutic Drugs Market (2021 to 2025) - Featuring Amgen, Baxter and China Biologic Products Among Others

Dublin, April 02, 2021 (GLOBE NEWSWIRE) -- The "Biologic Therapeutic Drugs: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.

Amgen to buy Five Prime Therapeutics in a deal valued at $1.9 billion to boost cancer treatment portfolio

Amgen Inc. announced Thursday an agreement to buy biotechnology company Five Prime Therapeutics Inc. in a cash deal valued at $1.9 billion. Five Prime shares were halted for news until 9 a.m. ET, while Amgen shares slipped 0.2%. Under terms of the deal, Amgen will pay $38.00 in cash for each Five …
Show more

Amgen Frequently Asked Questions

  • When was Amgen founded?

    Amgen was founded in 1980.

  • Who are Amgen key executives?

    Amgen's key executives are Robert A. Bradway, Victoria H. Blatter and Judy Gawlik Brown.

  • How many employees does Amgen have?

    Amgen has 23,400 employees.

  • What is Amgen revenue?

    Latest Amgen annual revenue is $25.4 b.

  • What is Amgen revenue per employee?

    Latest Amgen revenue per employee is $1.1 m.

  • Who are Amgen competitors?

    Competitors of Amgen include Viatris, Allergan and Novo Nordisk.

  • Where is Amgen headquarters?

    Amgen headquarters is located at 1 Amgen Center Dr, Thousand Oaks.

  • Where are Amgen offices?

    Amgen has offices in Thousand Oaks, Cambridge, Louisville, South San Francisco and in 54 other locations.

  • How many offices does Amgen have?

    Amgen has 63 offices.